JP5412293B2 - ブドウ球菌エンテロトキシンｂを中和する高親和性抗体 - Google Patents

ブドウ球菌エンテロトキシンｂを中和する高親和性抗体 Download PDF

Info

Publication number
JP5412293B2
JP5412293B2 JP2009544928A JP2009544928A JP5412293B2 JP 5412293 B2 JP5412293 B2 JP 5412293B2 JP 2009544928 A JP2009544928 A JP 2009544928A JP 2009544928 A JP2009544928 A JP 2009544928A JP 5412293 B2 JP5412293 B2 JP 5412293B2
Authority
JP
Japan
Prior art keywords
seq
antibody
antigen
sequence
seb
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2009544928A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010514459A (ja
JP2010514459A5 (enExample
Inventor
サス、フィリップ、エム．
ニコライデス、ニコラス、シー．
グラッソ、ルイージ
バーガー、マーク
サイ、タオ
Original Assignee
モルフォテック、インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by モルフォテック、インク． filed Critical モルフォテック、インク．
Publication of JP2010514459A publication Critical patent/JP2010514459A/ja
Publication of JP2010514459A5 publication Critical patent/JP2010514459A5/ja
Application granted granted Critical
Publication of JP5412293B2 publication Critical patent/JP5412293B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2009544928A 2007-01-03 2008-01-03 ブドウ球菌エンテロトキシンｂを中和する高親和性抗体 Active JP5412293B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US88327107P 2007-01-03 2007-01-03
US60/883,271 2007-01-03
US88840507P 2007-02-06 2007-02-06
US60/888,405 2007-02-06
PCT/US2008/000104 WO2008085878A2 (en) 2007-01-03 2008-01-03 High affinity antibodies that neutralize staphylcoccus enterotoxin b

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013126119A Division JP5881646B2 (ja) 2007-01-03 2013-06-14 ブドウ球菌エンテロトキシンｂを中和する高親和性抗体

Publications (3)

Publication Number Publication Date
JP2010514459A JP2010514459A (ja) 2010-05-06
JP2010514459A5 JP2010514459A5 (enExample) 2011-02-24
JP5412293B2 true JP5412293B2 (ja) 2014-02-12

Family

ID=39529113

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2009544928A Active JP5412293B2 (ja) 2007-01-03 2008-01-03 ブドウ球菌エンテロトキシンｂを中和する高親和性抗体
JP2013126119A Active JP5881646B2 (ja) 2007-01-03 2013-06-14 ブドウ球菌エンテロトキシンｂを中和する高親和性抗体
JP2016017809A Active JP6195946B2 (ja) 2007-01-03 2016-02-02 ブドウ球菌エンテロトキシンｂを中和する高親和性抗体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2013126119A Active JP5881646B2 (ja) 2007-01-03 2013-06-14 ブドウ球菌エンテロトキシンｂを中和する高親和性抗体
JP2016017809A Active JP6195946B2 (ja) 2007-01-03 2016-02-02 ブドウ球菌エンテロトキシンｂを中和する高親和性抗体

Country Status (9)

Country Link
US (6) US8236932B2 (enExample)
EP (2) EP3138852A1 (enExample)
JP (3) JP5412293B2 (enExample)
AU (1) AU2008205376B2 (enExample)
CA (2) CA2924155C (enExample)
DK (1) DK2109622T3 (enExample)
ES (1) ES2619943T3 (enExample)
PL (1) PL2109622T3 (enExample)
WO (1) WO2008085878A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8236932B2 (en) 2007-01-03 2012-08-07 Morphotek, Inc. High affinity antibodies that neutralize Staphylococcus enterotoxin B
WO2010030182A2 (en) * 2008-09-10 2010-03-18 Bac Ip B.V. Antigen-binding proteins that inhibit superantigens for the treatment of skin diseases
WO2013089877A2 (en) * 2011-09-27 2013-06-20 Albert Einstein College Of Medicine Of Yeshiva University Adjuvant therapy for staphylococcal infection with enterotoxin specific mabs
SG10201608341XA (en) * 2011-11-23 2016-11-29 Hoffmann La Roche Cd40l expressing mammalian cells and their use
US20160039914A1 (en) * 2013-03-14 2016-02-11 Albert Einstein College Of Medicine Of Yeshiva University Humanized antibodies specific for staphylococcal enterotoxin b
US10995152B2 (en) 2016-10-26 2021-05-04 The Board Of Trustees Of The Leland Stanford Junior University Modified immunoglobulin hinge regions to reduce hemagglutination
MX2019005772A (es) * 2016-11-23 2019-10-02 Bioverativ Therapeutics Inc Anticuerpos mono y biespecíficos que se unen al factor de coagulación ix y al factor de coagulación x.
KR102124258B1 (ko) * 2018-10-19 2020-06-26 대한민국(관리부서 질병관리본부장) 신속 면역크로마토그래피법을 이용한 황색 포도알균 장독소 b 진단·탐지 키트 및 이를 위한 특이항체와 항체생산세포주
JP7716399B2 (ja) * 2019-11-01 2025-07-31 ブイオーアール バイオファーマ インコーポレーテッド 抗－ｃｄ４５抗体及びそのコンジュゲート
KR102274759B1 (ko) * 2020-01-16 2021-07-09 대한민국(질병관리청장) 황색포도알균 장독소 b에 특이적인 항체 및 이의 용도
CN119101153B (zh) * 2024-04-30 2025-07-08 中国人民解放军军事科学院军事医学研究院 一种葡萄球菌肠毒素b纳米抗体及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2574089A (en) 1948-06-08 1951-11-06 Cochran Jacqueline Luggage case having a removable lining
US4854432A (en) 1988-07-06 1989-08-08 American Tourister, Inc. Suitcase having removable divider with clothing pockets
US6713610B1 (en) * 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
CA2194450A1 (en) 1994-07-06 1996-01-18 Truckin' Movers Corporation Convertible carrying case and work platform
US6036697A (en) 1998-07-09 2000-03-14 Scimed Life Systems, Inc. Balloon catheter with balloon inflation at distal end of balloon
WO2000020598A1 (en) 1998-10-07 2000-04-13 The Rockefeller University Peptides useful for reducing symptoms of toxic shock syndrome and septic shock
US8420353B2 (en) 2002-03-22 2013-04-16 Aprogen, Inc. Humanized antibody and process for preparing same
CA2496242A1 (en) 2002-08-21 2004-03-04 Merck Patent Gesellschaft Mit Beschraenkter Haftung T-cell epitopes in staphylococcal enterotoxin b
JP4571586B2 (ja) * 2003-09-05 2010-10-27 一般財団法人化学及血清療法研究所 プロテアーゼ耐性ｓｅｂ改変体およびそれを含むワクチン
CN101155832B (zh) * 2005-02-08 2013-02-06 一般财团法人化学及血清疗法研究所 抗体的改良方法
EA018030B1 (ru) * 2006-06-06 2013-05-30 Круселл Холланд Б.В. Связывающие молекулы человека, имеющие убивающую активность против стафилококков, и их применения
US8236932B2 (en) * 2007-01-03 2012-08-07 Morphotek, Inc. High affinity antibodies that neutralize Staphylococcus enterotoxin B

Also Published As

Publication number Publication date
CA2674382C (en) 2016-05-31
CA2924155C (en) 2020-02-11
JP2016146824A (ja) 2016-08-18
US9359428B2 (en) 2016-06-07
CA2674382A1 (en) 2008-07-17
EP2109622A2 (en) 2009-10-21
PL2109622T3 (pl) 2017-06-30
JP5881646B2 (ja) 2016-03-09
ES2619943T3 (es) 2017-06-27
US8895704B2 (en) 2014-11-25
AU2008205376A1 (en) 2008-07-17
US10364284B2 (en) 2019-07-30
EP2109622B1 (en) 2016-11-09
US20180094048A1 (en) 2018-04-05
US8236932B2 (en) 2012-08-07
DK2109622T3 (en) 2017-02-13
JP6195946B2 (ja) 2017-09-13
CA2924155A1 (en) 2008-07-17
JP2010514459A (ja) 2010-05-06
US20150050276A1 (en) 2015-02-19
US20130183314A1 (en) 2013-07-18
EP3138852A1 (en) 2017-03-08
US20120171223A1 (en) 2012-07-05
JP2013216673A (ja) 2013-10-24
US8889846B2 (en) 2014-11-18
US20170121396A1 (en) 2017-05-04
AU2008205376B2 (en) 2012-07-12
US9868780B2 (en) 2018-01-16
US20140072553A1 (en) 2014-03-13
WO2008085878A2 (en) 2008-07-17
WO2008085878A3 (en) 2009-02-26

Similar Documents

Publication Publication Date Title
JP6195946B2 (ja) ブドウ球菌エンテロトキシンｂを中和する高親和性抗体
CN105026428B (zh) PD‑l抗体、其抗原结合片段及其医药用途
WO2018208868A1 (en) Human monoclonal antibodies against lag3 and uses thereof
JP2021513331A (ja) 抗ｂ７−ｈ４抗体、その抗原結合断片及びその医薬用途
KR20110025859A (ko) 항-ｇｄ２ 항체 및 이와 관련된 방법 및 용도
TW201932491A (zh) 抗４－１ｂｂ抗體、其抗原結合片段及其醫藥用途
JP2011505381A (ja) シュードモナス・エルギノーサ（ＰｓｅｕｄｏｍｏｎａｓＡｅｒｕｇｉｎｏｓａ）のＰｃｒＶ抗原に対する抗体
JP7773239B2 (ja) Ｐｄ－ｌ１及びｃｄ４７に対する二重特異性単一ドメイン抗体及びその用途
JP7689116B2 (ja) Ｐｄ１およびｖｅｇｆｒ２二重結合剤
CN118804927A (zh) 抗b7-h7抗体或其抗原结合片段及制备方法和应用
KR20230158058A (ko) 시알산-결합 ig-유사 렉틴 15에 특이적인 항체 및 이의 용도
AU2012241059B2 (en) High affinity antibodies that neutralize Staphylococcus enterotoxin B
TW202506731A (zh) 治療多重抗藥性細菌感染之方法
CN120225558A (zh) 针对人程序性细胞死亡蛋白1(pd-1)的单克隆抗体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110104

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110104

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20110510

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130327

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130614

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20131015

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20131111

R150 Certificate of patent or registration of utility model

Ref document number: 5412293

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250